Biphasic malignant meningioma: a comparative genomic hybridization study.

Area of Science:

• Neuro-oncology
• Genetics
• Pathology

Background:

• Distinguishing between metastatic carcinoma in a meningioma and malignant progression within the meningioma is crucial for accurate diagnosis and treatment.
• Fibroblastic meningiomas can exhibit diverse histological features, sometimes including carcinoma-like areas, posing diagnostic challenges.

Observation:

• Immunohistochemistry for vimentin and epithelial membrane antigen showed strong reactivity in both fibroblastic and carcinoma-like components.
• Comparative genomic hybridization (CGH) revealed shared chromosomal alterations (losses of 1p, 14, 16p13-->p10, 22) between the two components.
• Distinct chromosomal alterations were also identified in each component, suggesting genetic instability and clonal evolution.

Findings:

• CGH analysis confirmed that the fibroblastic and carcinoma-like components are genetically related, originating from a common precursor.
• The genetic profile of the fibroblastic component indicated progression beyond typical benign meningioma alterations, consistent with atypical meningioma.
• The observed chromosomal gains and losses in both components support the hypothesis of malignant progression rather than a secondary metastatic carcinoma.

Implications:

• This study highlights the utility of CGH in differentiating metastatic disease from intrinsic malignant transformation in complex meningioma cases.
• Findings suggest that even histologically low-grade meningioma components can harbor genetic alterations indicative of early malignant progression.
• Understanding the genetic landscape of meningioma progression is vital for developing targeted therapies and improving patient outcomes.